Our results indicated that the survival rates decreased with increasing HK2 expression in OS, PFS, and DSS (Fig. 2A-C), whereas there was no correlation between HK2 expression and DFS in patients with gliomas (Fig. 2D). This evidence concerns the gene HK2 and central nervous system cancer.